NewLink Genetics (NLNK) IPO Trades Higher

November 11, 2011 10:45 AM EST
The IPO for NewLink Genetics Corporation (Nasdaq: NLNK) is open for trading. Shares are trading at $7.29 after pricing 6,200,000 shares a $7, which was below the expected $10-$12 range.

Stifel Nicolaus Weisel and Canaccord Genuity Inc. are acting as joint book-running managers for the offering, and Robert W. Baird & Co. Incorporated and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Stifel, Cantor Fitzgerald, Robert W Baird

Add Your Comment